Orchard Therapeutics Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orchard Therapeutics Limited
Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.
The company will likely have its answer in a matter of weeks, but a link to the vector would be a “worst-case scenario.”
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Orchard Therapeutics (Europe) Limited, Orchard Therapeutics North America